Home
Companies
Novo Nordisk A/S

Novo Nordisk A/S

Company

Also known as: Novo, Novo Nordisk

Company Profile

Novo Nordisk is a global healthcare company focused on defeating serious chronic diseases, especially diabetes and obesity. The company is active in more than 80 countries and markets products in about 170 countries worldwide.

Website: https://www.novonordisk.com
Headquarters: Bagsvaerd, Denmark
Founded: 1923
Stock Ticker: NYSE:NVO

Related News

Three Manufacturers Supply 90% of Global Insulin as Biosimilars Erode Oligopoly

Jun 28, 2026

The global insulin drugs and delivery devices market is dominated by three manufacturers supplying roughly 90% of volume, with biosimilar entry slowly eroding this oligopoly. The market is projected to see continued growth driven by rising diabetes prevalence, while pricing pressure from biosimilars and government policies accelerates. In the Middle East, the recombinant human insulin market is projected to expand at a 6–8% CAGR through 2035.

AstraZeneca Advances Oral GLP-1 Drug and Defends Diabetes Patent in Australia

Jun 19, 2026

AstraZeneca is advancing its oral GLP-1 drug into Phase III trials while defending dapagliflozin patents in Australia. The company obtained an Australian court injunction against a generic competitor and has partnered with Evinova to use AI for clinical trials. India could be a future market for the oral GLP-1 drug pending global trial data.

New GLP-1 Competition, FDA Approval, and Genomic Atlases Advance Drug Development

Jun 15, 2026

At the ADA Scientific Sessions, Novo Nordisk's Wegovy pill surpassed 3 million prescriptions within five months, while Structure Therapeutics and AstraZeneca shared mid-stage GLP-1 data targeting a 2029 launch. The US FDA approved TRUQAP as the first targeted treatment for PTEN-deficient metastatic prostate cancer, reducing disease progression risk by 19% in the CAPItello-281 trial. Meanwhile, two major genomic atlas projects—a 4,098-genome infant gut bacteria catalog and Basecamp Research's Trillion Gene Atlas—aim to advance precision probiotics and AI-driven drug discovery, respectively.

Delhi HC Clears Dr. Reddy's Semaglutide Export; Company Plans 60% Discount on Generic Wegovy

Jun 13, 2026

The Delhi High Court ruled Dr. Reddy's can export semaglutide, finding Novo Nordisk's patent unenforceable. Dr. Reddy's plans to launch generic Wegovy at 60% discount pending approval.

Life Sciences Outlook 2026: Growth, AI, and Activism Risks Shape Industry

Jun 02, 2026

The life sciences industry expects strong growth in 2026 driven by AI adoption and GLP-1 drug innovations, but faces headwinds from tariffs, FDA changes, and rising shareholder activism. Over 320 public activist campaigns have targeted life sciences companies since 2020, with 75-80% of biotech and pharma targets being pre-revenue firms.

Obesity treatments cost more in South Korea than in China and Japan

May 18, 2026

Wegovy and Mounjaro prices in South Korea are higher than in China and Japan. South Korea added both drugs to a non-insurance reporting system, but immediate price cuts are unlikely.

16 drugmakers announce TrumpRx pricing agreements and direct-to-patient discounts

May 12, 2026

Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.

Insulin costs and PBM scrutiny intensify pressure on drug affordability

May 10, 2026

Insulin list prices rose more than 300% over two decades as PBMs face growing scrutiny over rebates, spread pricing, and transparency. Reform efforts and pharmacist involvement are central to drug affordability and access.

As insurers drop GLP-1 coverage, patients lose access despite reported benefits

May 02, 2026

Vermont insurers and employers are scaling back GLP-1 coverage as costs rise, leaving some patients without access. The drugs remain in high demand as studies point to benefits beyond weight loss.

GLP-1 Drugs Show Mixed Effects on Brain Health: Neuroprotection Signals but Dementia Risk Questions

Apr 28, 2026

A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07607600	Treatment Patterns, Biochemical Profiles and Clinical Outcomes in Adults With X-Linked Hypophosphatemia	NOT_YET_RECRUITING
NCT07607587	Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events	NOT_YET_RECRUITING	PHASE1
NCT07605052	A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight	NOT_YET_RECRUITING	PHASE1
NCT07597018	A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity	NOT_YET_RECRUITING	PHASE1
NCT07587710	A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver Function	NOT_YET_RECRUITING	PHASE1
NCT07578584	A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or Obesity	NOT_YET_RECRUITING	PHASE1
NCT07571109	AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea	RECRUITING	PHASE3
NCT07571005	AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea	RECRUITING	PHASE3
NCT07570992	A Research Study to Evaluate the Safety of NNC1679-0001 When Given to Healthy Participants and Participants With T2DM	RECRUITING	PHASE1
NCT07567001	A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity	NOT_YET_RECRUITING	PHASE3